CHMP Rejects Serelaxin But Clears Albiglutide, Riociguat And Lurasidone
This article was originally published in The Pink Sheet Daily
Executive Summary
Europe’s top medical advisory panel turns down a new acute heart failure therapy from Novartis, but gives positive opinions to three other new active substances, from GlaxoSmithKline, Bayer and Takeda, following its Jan. 20-23 meeting.